Trial Profile

A Phase 2b Randomized Trial of Autologous Dendritic Cell Immunotherapy (CMN-001) Plus Standard Treatment of Advanced Renal Cell Carcinoma

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 05 Oct 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Rocapuldencel T (Primary) ; Everolimus; Ipilimumab; Lenvatinib; Nivolumab
Indications Renal cell carcinoma
Focus Therapeutic Use
Sponsors CoImmune

Most Recent Events

28 Sep 2023 Status changed from recruiting to discontinued.
06 Jul 2023 According to a CoImmune Media Release, the company announced the publication of a review of the companys clinical development program evaluating CMN-001to treat metastatic renal cell carcinoma in a Human Vaccines and Immunotherapeutics, a peer-reviewed journal sponsored by the International Society for Vaccines.
28 Jul 2022 Planned End Date changed from 1 Mar 2022 to 1 Mar 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com